RE:RE:RE:hot off the press. For what it's worth, Theralase completed it's GLP toxicology study of TLD1433 in September 2015 and commenced it's phase 1b NMIBC trial 15 months later.
99942Apophis wrote: Eoganacht wrote: Nice to see the GLP toxicology study moving onto the front burner. The sooner they start a phase 1b for gbm or nsclc the better.
The Company intends to use the proceeds of the Offering for the following:
Good Laboratory Practice ("GLP") toxicology study for intravenous installation of Rutherrin® intended for the treatment of Non-Small Lung Cancer ("NSCLC") and Glio Blastoma Multiforme ("GBM")......................................................................................
Exactly Eoganacht, this NR says a lot, which in my opinion is we know a thumbs up will be given by both FDA & HC for BTD. As you say NSCLC and GBM have been moved to the front burner because of the initiation of GLP. Judging length of time for that would be completed and ready for their next steps which could be roughly when either big pharma money starts flowing or as said SP has risen well beyond the $1 mark for another small financial raise.
Unfortunate news for those that sold off shares to sit on cash waiting for announcement of a PP, guess they will have to pay the price to get their shares back.
Yes sir this company has a very attractive future.